Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions
Aim: Although immunohistochemistry (IHC) and reverse transcription-PCR can detect ALK rearrangements, the ALK break-apart FISH assay is currently considered the standard method. Materials & methods: Five patients with advanced non-small-cell lung cancer, who had an ALK-negative FISH result that was later confirmed as positive by the Ventana IHC assay, were studied. Four had previously received chemotherapy or radiotherapy. All five were subsequently treated with Crizoitinib 250 mg twice daily. Results & conclusion: Four patients had a partial response to Crizotinib and one had stable disease. IHC is an efficient technique for diagnosing ALK rearrangements in patients with non-small-cell lung cancer, and may serve as an alternative to FISH in clinical practice.
基金：
Sun Yat-Sen University Cancer Center
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|4 区医学
小类|4 区药学
最新[2023]版：
大类|4 区医学
小类|4 区药学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Guangdong, Peoples R China;
通讯作者：
通讯机构：[1]Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714)：
Huang Jin-Lin,Zeng Jing,Wang Fang,et al.Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions[J].PERSONALIZED MEDICINE.2017,14(2):99-107.doi:10.2217/pme-2016-0080.
APA：
Huang, Jin-Lin,Zeng, Jing,Wang, Fang,Huang, Qi-Tao,Lu, Jia-Bin...&Lin, Su-Xia.(2017).Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions.PERSONALIZED MEDICINE,14,(2)
MLA：
Huang, Jin-Lin,et al."Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions".PERSONALIZED MEDICINE 14..2(2017):99-107
